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ABSTRACT

Behavioral effects of dopamine receptors were assessed in

11- and 17-day-old rat pups using irreversible dopamine
antagonist, EEDQ.

In Experiment 1, the locomotor activity

and sniffing behavior of 11- and 17-day-olds was assessed

after treatment with the nonselective dopamine receptor

agonist, NPA (6.00, 0.01, 0.1, 1.0, and 5.0 mg/kg).

Testing

sessions began 5-min after NPA treatment on three test days.
In Experiment 2, 10- and 16-day-old rat pups received a
single dose of EEDQ (7.5 mg/kg) or vehicle after dopamine
receptors were left either unprotected or protected using a
combination of sulpiride (100.0 mg/kg) and SCH 23390 (1.0
mg/kg).

NPA (0.00, 0.01, or 5.0 mg/kg) was then

administered to rat pups 24, 48, and 96 hours after EEDQ
treatment.

Results from Experiment 1 suggest that NPA did

not increase activity in 11-day-old pups; whereas, 17-day

olds showed an increase in activity, with 0.01 mg/kg NPA
producing the greatest effect.

NPA produced a dose-

dependent increase in sniffing in both aged pups.

In

Experiment 2, EEDQ did not affect the locomotor activity or

sniffing of 11-day-old pups; whereas, 17-day-olds showed
some enhancement of locomotor activity and sniffing after
EEDQ treatment.

Results indicate that the response of

preweanling and adult rats to EEDQ is fundamentally
different.

Possible explanations are discussed.
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INTRODUCTION

Dopamine systems have been implicated in a number of

important functions including attention, learning, and
movement.

Dopamine's role in the motor system has linked it

to conditions involving excessive, exaggerated, or bizarre
involuntary movements, such as in Huntington's chorea,
tardive dyskinesia, epilepsy, and Parkinson's disease.

L-

Dopa, a precursor to dopamine, increases the synthesis and
release of dopamine in Parkinson's patients, thereby

alleviating symptoms of tremors, difficulty in initiating
movement, loss of balance, and rigidity of limbs.

Chronic

administration of L-Dopa, as well as high doses of

amphetamine, cocaine, and other dopamine agonists produce
schizophrenic-like symptoms, such as hallucinations,
delusions, and disorganized thinking.

Drugs that block

dopamine activity decrease symptoms of schizophrenia,
suggesting that schizophrenia may be caused by an increase
in dopaminergic functioning.

Developmental disorders, such

as Tourette's syndrome and Lesch-Nyhan disease have also
been associated with dopamine systems (Calne, 1978, 1980;
Clark & White, 1987; Cote & Crutcher, 1985; Mason, 1984).

The important roles of dopamine systems, as well as the

severity of illnesses linked to dopamine systems, have

prompted many researchers to investigate dopamine

functioning.

Pharmacological studies have led to the

discovery of many drugs which exert various effects on

dopamine systems, drugs that help alleviate symptoms of
disease and neurological disorders, as well as those that

are used to provide an understanding of dopaitiinergic
functioning.

Ontogenetic studies also provide important

information on dopamine systems and their development.
Studies of the developing dopamine system contribute to an

understanding of normal functioning as well as abnormal
functioning.

Information on how these systems mediate

behavior in the developing animal also increase knowledge of
dopaminergic systems, which is the focus of the current

study.;

In studying the ontogeny of the nigrostriatal dopamine
system (a major ascending pathway in the CNS), several

issues need to be addressed:

dopamine Systems;
3.

2.

1.

the basic biology of

pharmaGology of dopamine systems; and

behaviors mediated by dopamine systems.

Biology of Dopamlne Systems
Biosynthesis of Dopamine

The synthesis of dopamine begins when the amino acid

tyrosine is converted to 3,4-dihydroxyphenylalanine (DOPA)
by tyrosine hydroxylase (Cooper, Bloom, & Roth, 1991).

The

next step involves the enzyme dopa decarboxylase (correctly
called aromatic L-amino acid decarboxylase) which
decarboxylates DOPA to dopamine in the cytoplasm of the

nerve cell (Cooper et al., 1991).

The dopamine is then

stored in the nerve terminals until it is required for

release.

Feedback inhibition is apparent in this system, as

tyrosine hydroxylase (rate-limiting substance) responds to

high or low levels of dopamine in the nerve terminals (Roth,
1979).

When dopamine levels are high, tyrosine hydroxylase

is prevented from catalyzing the formation of dopamine
(Roth, 1979).
Storage of Dopamine

There is evidence to suggest that dopamine is stored in
more than one pool (Groppetti et al., 1977).

Two distinct

pools with different rates of turnover have been described
(Nissbrandt & Carlsson, 1987).

There appears to be a

soluble or free storage pool in the cytoplasm which is
important for controlling dopamine synthesis by changing the

activity of tyrosine hydroxylase.

There is a second pool of

dopamine which is stored in granules (McMillen, German, &

Shore, 1980).

Release of dopamine is regulated by exocytosis from the
granule storage pool and is calcium dependent.

Newly

synthesized dopamine is preferentially released while
previously synthesized dopamine is stored and released under
aversive conditions only (McMilien et al., 1980).

The free

storage pool in the cytoplasm would first be transferred to
the granules before being released.

The substantia nigra in

the rat seems to release dopamine from only one pool
(Nissbrandt & Carlsson, 1987).

Dopamine release from the striatum is also regulated by
cell firing rates and inhibitory autoreceptors that exist on
the presynaptic neuron (Carlsson, 1975; Wolf & Roth, 1990).
Metabolism of Dopamine

The two main enzymes involved in the metabolism of
dopamine are monoamine oxidase (MAO) and catechol-0

methyltransferase (COMT).

MAO converts dopamine to

3,4-dihydroxyphenylacetaldehyde which is then converted to
3,4-hydroxyphenylacetic acid (DOPAC).

DOPAC is converted to

homovanillic acid (HVA) by COMT (Nissbrandt & Carlsson,

1987).

COMT is particularly important for the extracellular

degradation of dopamine (Gulderg & Marsden, 1975). Reuptake
of dopamine into the presynaptic terminal, and not enzyme
degradation, is the primary method of termination for
dopaminergic action in the synapse (Baldessarini, 1975;

Iversen, 1978).

The uptake of dopamine is mediated by a

carrier mechanism in the membrane of the presynaptic
terminal and cell body region (Geffen, Jessell, Cuello, &

Iversen, 1976; Harris & Baldessarini, 1973).

A second

noncarrier mediated uptake system has been described
accounting for approximately 10-^30% of dopamine uptake

(Krueger, 1990).

The uptake system also functions as a

receptor or binding site for many psychoactive compounds
such as tricyclic antidepressants and the psychomotor
stiiaulants (Bradford, 1986; Randrup & Braestrup, 1977).
Dopamine Receptors

Dopamine receptors have been divided into subtypes,
the first two to be classified were; Dl, which activates

adenylyl cyclase when stimulated; and D2 which is thought to
be uncoupled to adenylyl cyclase or coupiled in an inhibitory
manner (Kebabian, 1978; Kebabian & Calne, 1979; Spano,
Govini, & Trabucchi, 1978).

Further research has revealed

D3, D4, and D5 receptors, although they have not yet been

fully characterized (Sokoloff/ Giros, Martres, Bouthenet, 5e
Schwartz, 1990; Sunahara et al., 1991; Van Tol et al.,
1991).

In the nigrostriatal system, most of the dopamine
receptors lie on the dendrites or on the soma of neurons

postsynaptic to dopamine containing neurons.

In the ;

striatum, the Dl receptors out number D2 receptors 3 to 1

(Boyson, McGonigle, & Molinoff, 1984; Rao, Molinoff, &
Joyce, 1991).

Dopamine receptors have also been found presynaptically
on dopamine containing neurons, on somatic-dendritic regions

and on nerve terminals.

Th(2se receptors are called

autoreceptors and are important in the local regulation of

nerve impulse flow, dopamine synthesis, and dopamine rielease
(Wolf & Roth, 1987).

Autoreceptors are more sensitive to

dopamine agonists than postsynaptic receptors (Roth, 1979;
Wolf & Roth, 1987).

Dopamine autoreceptors are thought to

be of the 02 receptor Subtype (Wolf & Roth, 1987), however,

preliminary evidence suggests that the D3 subtype may also

exist as an autoreceptor.

Dopamine autoreceptors also

influence tyrosinehydroxylase activity by interfering with
the phosphorylation of the enzyme (Wolf & Roth, 1987).
Ontocenv of Dopamine Svstems

The dopamine systems, with its many components, are

typically present in the rat pup at birth.

Dopamine is

present at 12-13% of adult levels on postnatal day (PD) 0 in
the striatum and slowly increases until adulthood (Coyle &

Henry, 1973; Ribary, Schumlpf, & Lichtensteiger, 1986).
Activity and conduction of dopaminergic neurons in the
substantia nigra to the terminal regions of the striatum are
evidenced on PD 0 (Tepper, Trent, & Nakamura, 1990). Neurons
are near or at mature rates between the third and fourth

postnatal weeks (Tapper et al., 1990).

Release mechanisms

are mature at PD TO (Walters, Chapman, & Howard, 1990).

MAO

and COMT, the degradative enzymes, can be detected at

gestation day (GO) 15 in the striatum (Fiszman, Zuddas,

Masana, Barker, & di Porzio, 1991).

By GO 16, high affinity

dopamine uptake mechanisms are functioning (Fiszman et al.,
1991).

Ontogenetic increases in uptake binding sites are

seen as early as PD 3 when binding sites reach 22% of adult
levels and adult levels are reached by PD 39 (Bonnet &
Costentin, 1989).

Dopamine receptors are at a low level at birth, with Dl
receptors at 9-14% of adult levels and D2 receptors at 9%

(Murrin & Zeng, 1986; Rao et al., 1991).

There is

disagreement in the literature as to when these receptors
reach adult levels.

Several studies have shown Dl receptor

levels to reach a peak between PD 28 and PD 40 and then

decline to adult levels (Gelbard, Teicher, Faedda,
Baldessarino, 1989; Giorgi et al., 1987; Rowlett, Rice,

McDougall, Bardo, & Pedigo, 1991).

However, another study

suggests that adult levels for Dl receptors are reached by

the end of the third postnatal week (Zeng, Hyttel, & Murrin,
1988).

Rao et al. (1991) found that Dl receptors reached

adult levels at PD 16, although adulthood was defined as 60

PD for this study; whereas, others used 70-120 PD as the

criteria.

Adult levels for D2 receptors are reached after

30 to 60 postnatal days, with adulthood defined as 60-day
olds (Murrin & Zeng, 1986; Rao et al., 1991).

With D2

receptors there appears to be a linear increase from birth,
although, other results indicate that D2 receptors peak at
PD 40 and then decrease to adult levels (adults were defined
as 120-day-olds).

It does not appear that rat pups have functional
autoreceptors until PD 35.

As shown by Shalaby & Spear

(1980), attenuation of locomotor activity does not occur to
low doses of apomorphine in rat pups under PD 35.

Electro-

physiological studies indicate that autoreceptors do not

develop until at least four weeks after birth (Pitts,
Freeman, & Chiodo, 1990).
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Pharmacological Effects of Dopamine Systems

D1 and D2 receptors show different affinities for

endogenous dopamine, with D1 having a ten times higher
affinity than D2 (Hess & Creese, 1987; Seeman & Niznik,
1988).

The recently classified dopamine receptor subtypes

(i.e., D3, D4, and D5) also show different affinities for
endogenous dopamine (Sokoloff et al., 1990; Sunahara et al.,
1991; Van Tol et al., 1991).

Recently, the development of selective and non-

selective dopamine-acting drugs has led to a rapid increase
in knowledge about dopamine system functioning.

Specific Dl

receptor agonists (drugs that bind to and activate only Dl
receptors) include SKF 82958 (O'Boyle, Gaitanopoulous,
Brenner, & Waddington, 1989); whereas, partial agonists are;
SKF 89641 and SKF 89145 (both theinopyridines derivatives),
and SKF 38393 (a benzazapine compound) (Lorio, Barnett,
Leitz, Houser, & Korduka, 1983; Sibley, Leff, & Creese,
1982).

A selective antagonist for the Dl receptor (drugs

that block Dl receptors) is SCH 23390.

Specific agonists

for D2 receptors are quinpirole and bromocriptine;

antagonists include sulpiride and other benzamides (Clark &
White, 1987).

Nonselective dopamine receptor agonists (drugs that
bind to and activate the various dopamine receptor subtypes)

include:

N-propylnorapomorphine (NPA), apomorphine, and

ADTN; whereas, nonselective antagonists include: cis(Z)-

Fliipentixol, cis{Z)-Piflutixol, and cis(Z)-Clopentixol.
Although apomdrphine has been widely used in research, it
has recently been shown to be more selective than NPA in

actiyating D2 than D1 receptors (Goldman & Kebabian, 1984;
Seeman & Grigoriadis, 1987).

IIPA. and apdmorphine haye also

been shown to have a greater potency at presynaptic sites
than at postsynaptic sites (Meller, Goldstein, Friedhoff, &
Schweitzer, 1988).

EEDQ is a peptide coupling agent which noncompeti
tively binds to dopamine receptors and depletes both D1 and
D2 receptors (Crawford, McDougall, Rowlett, & Bardo, 1992).
It has been used to determine age-dependent and regional
differences in dopamine receptor turnover and recovery for
both D1 and D2 binding sites (Battaglia, Norman, & Creese,

1987; Fuxe, Agnati, Pich, Meller, & Goldstein, 1987; Leff,

Gariano, & Creese, 1984; Norman, Battaglia, & Creese, 1987).
EEDQ also inactivates alpha-adrenergic, serotonin and GABA
receptors, however by protecting dopamine receptors,
behaviors mediated by dopamine can be differentiated from
behaviors mediated by other receptors.

Receptors can be

protected by using specific D1 and 02 antagonists such as
SCH 23390 and sulpiride.

These selective antagonists block

01 and 02 receptors, thereby eliminating EEOQ's ability to
inactivate those specific receptor subtypes (Henry, Joseph,
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Kochman, & Roth, 1987; Leff et al., 1984).

Studies have

shown that behavioral recovery is correlated with recovery

of dopamine receptors (Hamblin & Creese, 1983).
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Behaviors Mediated by Dopamine Systems
Adult studies

Dopamirve systems play a critical role in motor control.

For example, when dopamine agonists are administered to
rats, there is a decrease in locpmotor activity at low doses
and an increase in motor activity at high doses (Arnt,

1987).

Stereotyped behaviors shch as sniffing, rearing/ and

head movements, as well as oral dyskinesias are produced at
even higher doses,

A decrease in behavior is produced by

dopamine antagohists, including suppression of conditioned
responses (Arnt, 1987).

Dl receptors are involved in grooming, perioral
activity, and perhaps non^stereotyped locomotor activities
(Clark & White, 1987).

D2 receptors are involved in

locomotor activity, sniffing, yawning, and rearing (Arnt,
Hyttel, & Perregaard, 1987; Dall' Olio, Gandolfi, Vaccheri,

Roncada, & Montanaro, 1988; Longoni, Spina, & DiChiara,
1987; Molloy & Waddington, 1985).

Dl and D2 receptors

appear to interact to affect behavior.

For example,

grooming behaviors mediated by Dl receptors are attenuated
by excessive D2 activation.

In addition, Dl receptor

systems appear to play a 'permissive' role for D2 agonist
induced behaviors, as Dl antagonists block the enhanced

sniffing, yawning, and locomotor activity induced by D2
agonists (Arnt, Hyttel, & Meier, 1988; Longoni et al., 1987;
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McDougall/ Arnold, & Nonneman, 1990; Pugh, p'Boyle, Molloy,
& Waddington, 1985; Serra, CollUj & Gessa, 1987).

It also

appears that a functioning D2 system may be necessary for

activating D1 mediated grooming behavior (Gandolfi,
Dall'Olio, Vaccheri, Rohcada, & Montanaro, 1988; Murray &
Waddington, 1989).

Stereotyped behaviors such as: licking,

biting, climbing, and gnawing are fully exhibited only after
treatment with a combination of D1 and D2 agonists or mixed

agonists (Arnt & Hyttel, 1985; Bordi & Meller, 1989; Davis,
Jenner, & Marsden, 1990; Longoni et al., 1987).

Additive

effects are sometimes produced by antagonism of both 01 and
02 receptors (Arnt & Hyttel, 1985; McOougall, Nonneman, &

Crawford, 1992; Waddington, 1989).

Adult-like interactions

of 01 and 02 receptors have also been shown in preweanling
rats as young as ll-days-old (McOougall et al., 1990).
Ontoaenetic Studies

Developmental studies of 01 and 02 receptors use

similar compounds as those used for adult rats.

Quinpirole,

a 02 selective agonist, increases locomotor activity in both
11-and 17-day-old rat pups (McOougall et al., 1990).

The

selective 01 agonist, SKR 38393, produces enhanced grooming

and, at high doses, increased locomotor activity (McOougall

et al., 1990).

interactive effects of 01 and 02 receptors

are found when SCH 23390, a selective 01 antagonist, blocks
quinpirole-induced increases in locomotor activity
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(McDougall et al., 1990).

Moody and Spear (1992) assessed

ontogenetic differences in neonatal (PD 3-4), prewe^anling
(PD 10-11), and weanling (PD 21-22) rats.

They found age-

related responses to D1 and D2 receptor stimulation with

separate and combined administration of D1 and D2 agonists.
All ages showed increases in locomotor activity and sniffing
to separate and combined administrations of SKF 38393 and
quinpirole.

Contrary to McDougall et al.'s results, adult-

typical grooming responses were only seen in weanling aged
rats in response to SKF 38393, due perhaps to a lower dosage

of SKF 38393 used by Moody and Spear.

Increases in vertical

movements and licking were also seen only in the weanling

aged rats in response to quinpirole or SKF 38393 combined or
separately.

Their results suggest that D1 and D2 receptors

are functually operative after agonist stimulation at even

early ages, although differences in blood brain barrier
permeability, absorption rates, and other aspects of

dopamine functioning do show ontogenetic changes (Moody &
Spear, 1992).

Learning studies in young rats have also provided
information on ontogenetic differences in response to

dopamine receptor agonists and antagonists.

Response

suppression learning of yohnger (11- and 13-day-old) and
older (17- and 19-day-old) rat pups was compared after 02

receptor activity was blocked with the antagonist sulpiride
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(McDougall & Nohneman,

The researchers found

dlfferehces in responding between the ll-and l7-da.y-pld

rats, as sulpiride had no effect on the 11-day-olds punished
responses; whereas, the punished responding of 17-day-old
rats was disrupted by sulpiride.

These results suggest that

some maturation of the D2 system may occur between 11- and

17-days of age accounting for differences in response to
sulpiride (McDougall & Nonneman, 1989).
Recent studies have shown that rat pups do not show

drug sensitization until after 21 PD (Kolta, Scalzo, Ali, &
Holson, 1990).

Habituation is a decrease in response to a

novel environment.

Drug sensitization occurs when there is

an overresponiveness to a drug after repeated administra
tion.

Drug sensitization and habituation research on 17

day-old pups showed stable levels of activity when treatment

consisted of successive NPA treatment for three testing days
(NNN) (McDougall, Crawford, & Nonneman, 1992).

However,

rats given saline for two days and NPA (SSN) on the third
testing day did exhibit higher activity levels than saline

subjects (SSS) and less than those in the NNN group

(McDougall, Crawford, & Nonneman, 1992).

Habituation to the

chamber decreased the number of activity counts, although
the pattern of responding was similar for both nonhabituated
and habituated groups (McDougall, Crawford, & Nonneman,

1992).

^
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^

,

Mature rats and preweartling rats differ in their
responses to EEDQ.

McDougall, Crawford, and Nonneman (1992)

found that EEDQ does not attenuate the typical dopaniine
agonist induced behaviors such as grooming and lOCoinotor
behavior in young rats.

Crawford et ar.. (1992) tested D1

and D2 binding sites for depletion after EEDQ treatment and

found that 17-day-oid rats showed a smaliejr relative
decrease of receptors (69%) when compared to adult rats (86%

depletion rate).

In a recent experiment with 11- and 17

day-old rat pups, it was found that although depletion of
receptors was similar after EEDQ treatment, full recovery
did not occur for the 11-day-olds even after eight days

(Crawford, Rowlett, McDougall, Elkins, & Bardo, 1991).
These results indicate that there are interesting
ontogenetic differences in the responses of various aged
rats to EEDQ.

First, the behaviors of 90-day-old rats, but

not 17-day-olds, are affected by EEDQ (ll-day-old rats have
never been tested behaviorally after EEDQ).

Second, 17- and

90-day-old rats show full receptor recovery after EEDQ

treatment, but 11-day-olds do not.

Thus, it is unclear what

effect EEDQ should have on the behaviors of ll-day-old rats.
This proposal will further assess the behavioral effects of
EEDQ on 11- and 17-day-old rats.

The age-dependent differences in receptor

neurochemistry between 11- and 17-day-old rat pups leads to
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the question of whethei: ll'^day-olds should respond

differently to EEDQ.

In studies involving learned

behaviors, striking age-dependent behavioral differences

have been observed after treatment with dopamine-acting
drugs (McDougall & Nonneman, 1989); however, when unlearned

behaviors were assessed using similar drugs, few age-

dependent differences have been reported (McDougall et al.,
1990).

since EEDQ produces profound neurochemical

differences between 11- and 17-day-old rats, it is expected
that this will be reflected behaviorally.

Since no

behavioral data has been obtained on ll-day-old pups over
time, the present investigation will establish a dose
response curve in 11- and 17-day-olds, as well as test NPA

in the ll-day-qlds for the first time-

Experiment 1 will

involve testing various NPA dosage levels on both 11- and
17-day-old rat pups.

Sniffing is maximally produced by

joint D1 and D2 stimulation and should be fully observed at
high doses of NPA.

Locomotor activity reflects increased D2

receptor activation, and should be observed after lower
doses of NPA.

As stated previously, EEDQ's behavioral effects are
different for 17- and 90-day-old rats, as EEDQ does not

affect the locomotor activity and grooming of NPA-treated
17-day-old rats (McDougall, Crawford, & Nonneman, 1992).

It

is possible that the lack of an EEDQ-induced effect in the

17

17-day-old rats is because the behaviors assessed require
only a small percentage of available dopamine receptors.
Therefore, in Experiment 2, a high dose of NPA will be used,
which should produce a stereotyped sniffing response.

This

behavior requires a full complement of dopamine receptors,

thus an EEDQ-induced decrease in sniffing should, therefore,
be observed in the 17-day-old rats.

Because full receptor

recovery is not apparent in EEDQ treated 11-day-old rats, it
is uncertain how they will respond behaviorally after EEDQ
treatment.
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Method

Subjects.

Animals were 80 male and female rats of

Harlan Sprague-Dawley descent, born and reared at California
State University of San Bernardino.
defined as day 0.

days of age.

The day of birth was

Litters were culled to 8-10 pups at three

Pups were caged with dam except during experi

mental procedures.

Assignment of subjects was random with

eight animals selected in each group.

The colony room was

maintained at 28°C and kept under a 12:12 hr light;dark
cycle.

Testing was conducted during the light phase of the

cycle.. .

Apparatus.

Behavioral testing Was done in activity

chambers made of plywood (25 X 25 X 18 cm) with a wood floor

and an open top. Walls and floor were painted gray.

The

floors were divided by black lines into four equal
quadrants.

The testing chambers were housed in a large

glass-topped incubator maintained at 31 + 1°C.

Clear

Flexiglas heated holding cages with hardwood chip bedding
were used to hovase pups before behavioral testing.
Procedure and Drugs,

pifferent doses of NPA (0, 0.01,

0.1, 1.0, and 5.0 mg/kg) were administered 5 minutes prior
to observation of 11- and 17-day-old rats.

Each pup was

tested at only one age and each pup received only one drug
sequence.

Each subject was individually habituated to the

19

testing chamber for 20 minutes prior to injection of the

agonist.

Locomotor activity (number of line crossings) and

sniffing behavior were assessed for a 20 minute testing
session (Test Day 1).

Behaviors of the same rats were then

assessed after drug treatment on two subsequent test days

(Test Days 2 and 4).

A single line^crosslng was defined as

the rat pup placing two front paws into an adjacent

quadrant.

Sniffing was measured every 20 seconds during the

session using a time sampling technique.

Sniffing was

defined as a head down movement, in which the nose and

whiskers visibly moved.

Eight subjects were used in each

group.

All drugs were injected intraperitoneally (i.p.) and

were given at a volume of 5.0 ml/kg.

NPA was obtained from

Research Biochemicals INC. (USA) and dissolved in saline
prior to injection.
Statistics.

Two 5 X 2 univariate analyses of variance

(ANOVAs) with repeated measures were used for statistical
analysis of locomotor activity and sniffing data.

The three

test days were analyzed as a repeated variable and dose (0,
0.01, 0.1, 1.0, and 5.0) was analyzed as a between factor.

One-way ANOVAs were used to further examine significant
interactions.

Newman-Keuls' tests supplemented ANOVAs when

appropriate (p < 0.05).
Results
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Locoinotor Activity.

A significant two-way interaetiori

betwean dosage level and day was found for both 11- and 17
day-old rat pups (F(8,70) = 7.87; p <0.001 and F(8,70) ^

6V39, p< 0.001, respectively) (see Figure 1).

On Day 2/

11-day-old pups were significantly less active after
treatment with 5.0 mg/kg NPA, as compared to the saline-

treated pups (p < 0.05).

The effects of dose yaried

significantly on Days 2 and 4 for 11-day-old pups, with the
NPA-treated animals being in general less active; F(4,39) 
3.286, p < 0.05 and F(4,39) - 7.503, p <0.001,

respectively.

All dosage levels of NPA (0.01/ 0.1, 1.0 and

5^0 mg/kg) significantly decreased locOmotor activity in 11
day-olds on Day 4 (p < 0.05).

Saline-treated rats showed a

progressive increase in locomotor activity across days, due

possibly to maturational effects (i.e. opening of eyes),
F(4,39) = 99.72, p < 0.001.

Surprisingly, NPA-treated pups

did not show a day-dependent effect.
Seventeen-day-old pups also displayed significant drug-

dependent differences in activity on Days 2 and 4 (F(4,39) =
8.243, p < 0.001 and F(4,39) = 19.284, p < 0.001,

respectively).

When assessed across days, saline-treated

17-day-old rats showed a significant decline in locomotor

activity, perhaps due to habituation effects (p < 0.05).

In

contrast all doses of NPA increased activity significantly
from Day 1 to Day 2 (p <0.05), then leyelfed off.
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old rat pups in Experiment 1 by NPA dosage on each test day

FIGURE 1 Mean number of line-crossings for 11- and 17-day
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Sniffing.

Significant main effects for day and dosage

were found for both 11- and 17-day-olds (F(8,70) = 5.30, £ <

0.001 and F(8,70) = 2.77, E < 0.010, respectively) (see

Figure 2).

In all cases, NPA produced significantly higher

sniffing counts than saline; moreover, the greater doses of
NPA (5.0 and 1.0 mg/kg) produced significantly higher counts
of sniffing than the lower doses (0.01, and 0.1) for both
11- and 17-day-old rats (p < 0.05).

For 11-day-old pups,

sniffing in the 5.0 mg/kg NPA group increased significantly
over the three testing days; whereas, all other doses showed

significant increases from Day 1 to Day 2 only (p < 0.05).

Summary.

The purpose of Experiment 1 was to determine

the doses of NPA which produced maximal sniffing and
locomotor activity.

Results indicated that 0.01 mg/kg NPA

led to the most pronounced increase in locomotor activity in
17-day-olds.

Since NPA-treated 11-day-olds were

significantly less active on Days 2 and 4, compared to
saline-treated pups, it is more difficult to ascertain an
appropriate dosage level.

Therefore, 0.01 mg/kg NPA was

chosen as the low dose in Experiment 2.

Sniffing for both

11- and 17-day-olds was significantly enhanced by 5.0 mg/kg

NPA leading to its choice as the high dose for Experiment 2.
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Experiment 2

It has previously been shown that EEDQ does not affect
NPA-induced locomotor activity in 17-day-old rat pups

(McDougall, Crawford, & Nonneman, 1992).

It is quite

possible that this paradoxical effect is due to a large
number of spare receptors in the 17-day-old rat.

Thus,

although EEDQ inactivates at least 65% of striatal dopamine
receptors in 17-day-olds (Crawford et al., 1992), it is
possible that a sufficient number of receptors remain to
mediate agonist-induced effects (see McDougall, Crawford, &

Nonneman, 1992).

In contrast to locomotor activity, drug-

induced sniffing requires that a large percentage of D1 and

D2 receptors must be activated for the behavior to occur
(Arnt et al., 1988; Longoni et al., 1987; McDougall et al.,

1990).

This feature suggests that sniffing should be much

more sensitive to EEDQ's effects.

Therefore, in Experiment

2, the NPA-induced sniffing of 11- and 17-day-old pups was
assessed after EEDQ treatment.

In addition, by using both a

high and low dose of NPA, it will be determined behaviorally
if there are significant ontogenetic differences in recovery
of dopamine D1 and D2 receptors for 11- and 17-day-old rat
pups.
Method

Subjects and Apparatus*

Subjects were 144 male and

female rat pups of Harlan Sprague-Dawley descent, born and
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reared at California State University, San Bernardino.

Rearing conditions and apparatus were the same as in
Experiment 1.

Procedure and Drugs. Using 0.01 and 5.0 mg/kg NPA, ll

^ud 17—day—old rats were tested for receptor recovery after
EEOQ treatment.

Rats from both age groups were divided into

two conditions - protected or nonprotected condition.

^^ot®c:ted subjects received two injections of dopamine

antagonists to block receptors from EEDQ inactivation (this
allows assessment of nondopaminergic effects of EEDQ). Rats

in the protected condition were given an initial injection
of sulpiride (100.0 mg/kg) followed, 30 min later, by an
injection of SCH 23390 (1.0 mg/kg). The nonprotected rats
received two injections of vehicle. Thirty minutes after

the second injection, rats were injected with either EEDQ

(7.5 mg/kg) or its vehicle. (A protected/vehicle group was
not included, since protection has not been shown to

significantly affect behavior.) For each rat, behavioral

testing occurred 1, 2, and 4 days after initial drug
treatments. On each of these test days, rats were injected
^ith either saline or NPA (0.01 and 5.0 mg/kg). Each rat
was given the identical treatment three times across a four

day span. Five minutes after agonist treatment, locomotor
activity and sniffing were recorded in the same manner as in
Experiment 1.
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All drugs were injected i.p. and were given at a volume

of 5.0 ml/kg.

Both sulpiride and SCH 23390 were dissolved

in distilled water, with the former drug requiring a small

volume of glacial acetic acid.

EEDQ was dissolved in 95%

ethanol:distilled water (1:4).

EEDQ (N-ethoxycarbonyl-2

ethoxy-1,2-dihydroquinoline) was acquired from Sigma (USA).
Sulpiride and SCH 23390 were obtained from Research
Biochemicals Inc. (USA).
Statistics.

Repeated measures 3X3X3 ANOVAs were

used to examine locomotor activity and sniffing.

test days were treated as a repeated variable.

The three

NPA and EEDQ

were separated into three levels: saline, 0.01 mg/kg, and
5.0 mg/kg NPA; protected/EEDQ, nonprotected/EEDQ, and

nonprotected/vehicle.

Two- and one-way ANOVA's were used to

further examine significant interactions.

Newman-Keuls'

tests supplemented ANOVAs when appropriate (p < 0.05).
Results

Locomotor Activitv.

No three-way interaction was found

for 11-day-old pups (F(8,126) = 1.07, p > 0.05).

The only

interaction for 11-day-olds was between NPA and day

(F(4,126) = 7.32, p < 0.001) (See Figure 3).

A significant

main-effect on Day 1 was found for NPA (F(2,69) = 7.935, p <

0.001).

Eleven-day-old pups were significantly more active

with the lower dose of NPA (0.01 mg/kg) than with 5.0 mg/kg
or saline (p < 0.05).

On Day 2 (£(2,69) = 7.745, p <
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FIGURE 3 Mean number of line-erossings for 11- and 17-day
old rat pups in the three EEDQ pretreatment conditions of
Experiment 2 by NPA dosage on each test day.
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0.001), saline-treated pups showed significantly higher

levels of activity than 11-day-dlds treated with 5.0 mg/kg
NPA (e < 0.05).

Higher activity counts were also produced

by 0.01 mg/kg NPA on Day 2, when compared with 5.0 mg/kg (p
< 0.05).

Saline-treated rats displayed significantly higher

activity counts on Day 4 (F(2,69) = 12.121, p < 0.001), than

either 0.01 or 5.0 mg/kg NPA (p < 0.05).

For 11-day-olds treated with saline, significant
increases in activity were seen from Day 1 to Day 2 (p <
0.05); this increase leveled off on Day 4.

Significant

increases in locomotor activity were also seen from Day 1 to
Day 2 for 11-day-olds treated with 0.01 mg/kg NPA.
Significant three-way interactions between NPA, EEDQ,
and day were found for 17-day-old pups (F(8,126) = 2.01, p <

0.050) (See Figure 3).

Two-way interactions between EEDQ

and day, and NPA and day were also significant for 17-day
olds (F(4,126) = 2.59, p < 0.040, and F(4,126) = 4.14, p <

0.003, respectively).

Significant two-way interactions

between NPA and EEDQ were found on Day 2 (F(4,63) = 4.642, p

< 0.002) for 17-day-old pups.

Activity counts of pups

treated with 0.01 mg/kg of NPA were significantly lower on
Day 2 while when in the protected/EEDQ group rather than the
unprotected/EEDQ or unprotected/yehicle group (p < 0.05).
When given 5.0 mg/kg NPA, both unprotected/EEDQ and
protected/EEDQ groups showed significantly lower levels of
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activity than the unprotected/vehicle group (p < 0.05).

The

protected/EEDQ group treated with saline had significantly
higher counts of activity for Day 2 than the
unprotected/vehicle group (p < 0.05).

On Day 1, unprotected/EEDQ pups treated with 0.01 mg/kg
NPA had significantly higher locomotor activity counts than
saline-treated pups in the unprotected/EEDQ,

unprotected/vehicle, or protected/EEDQ groups; 5.0 mg/kg NPA
treated pups in the protected/EEDQ group also had

significantly lower activity counts than 0.01 mg/kg treated

unprotected/EEDQ pups (p < 0.05).

For 17-day-old pups in

the unprotected/vehicle group, activity increased
significantly from Day 1 to Day 2 for pups in the 0.01 and
5.0 groups, and then leveled off (p < 0.05).

Saline-treated

pups showed significantly lower levels of activity on Day 4
in all three conditions than either 0.01 or 5.0 mg/kg NPA

treated pups (p < 0.05).

Unprotected/vehicle pups given

0.01 mg/kg NPA were significantly more active than
unprotected/EEDQ pups given 5.0 mg/kg on Day 4 (p < 0/05).
Sniffing.

As with the locomotor activity results, 11

day-olds showed no significant three-way interaction

(F(8,126) = 0.80, p > 0.05) (See Figure 4).

A significant

two-way interaction was found for NPA by day for 11-day-olds

(F (4,126) = 8.60, p < 0.001).

Saline-treated 11-day-old

pups had significantly lower levels of sniffing than either
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old rat pups in the three EEDQ pretreatmeht conditions of
Experiment 2 by NPA dosage on each test day.
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0.01 or 5.0 mg/kg NPA (e < 0.05).

On Days 2 and 4, (F(2,69)

=43.795, E < 0.001 and F(2,69) = 123.240, E < 0.001,

respectively) 5.0 mg/kg produced significant increases in
activity compared with 0.01 mg/kg NPA (e < 0.05).

Over the four testing days, there was a significant
increase in sniffing for 5.0 mg/kg NPA treated 11-day-olds

(E < 0.05); all other doses remained stable with EEDQ having
no significant effect.

Significant three-way interactions between NPA, EEDQ,

and day were present for the 17-day-old pups (F(8,l26) =
4.76, E < 0.001) (See Figure 4).

Significant twO-way

interactions for the 17-day-olds included EEDQ by day
(F(4,126) = 3.73, E < 0.001), and NPA by day (F(4,126) =

6.52, E < 0.007).

Significant interactions between EEDQ and

NPA were found for 17-day-old rats on Days 1 and 2 (F(4,63)
= 5.462, E < 0.001 and F(4,63) = 7.253, E < 0.QOl).

On Day

1, the protected/EEDQ group had significantly more sniffing
counts than the unprotected/EEDQ and unprotected/vehicle
groups when treated with 0.01 mg/kg NPA (p < 0.05).
Moreover, on Day 1, treatment with 5.0 mg/kg NPA produced

significantly higher counts of sniffing for protected/EEDQ
and unprotected/EEDQ groups, compared with the

unprotected/vehicle group (p < 0.05).

On Day 2, 0.01 mg/kg

produced the least amount of sniffing in unprotected/vehicle
pups, rather than pups in the other two conditions (p <
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0.05).

On all three test days, saline-treated pups had

significantly lower levels of sniffing in all three
conditions; whereas 5.0 mg/kg NPA produced the highest
counts, significantly higher than 0.01 mg/kg treated pups on

Days 1 and 4 in all three conditions (p < 0.05).

On Day 2,

5.0 mg/kg produced significantly more sniffing counts than
0.01 mg/kg in the unprotected/vehicle and protected/EEDQ
conditions (p < 0.05).

A significant increase from Day 1 to

Day 2 was noted for pups given 0,01 mg/kg NPA in the
unprotected/EEDQ condition (p < 0.05).

Summary.

For 11-day-old pups, EEDQ did not appear to

affect Idcomotdr activity, as the protected/EEDQ and

unprotected/EEDQ conditions reflected similar patterns of

activity as the unprotected/vehicle condition.

As in

Experiment 1, on Days 2 and 4 saline-treated pups showed

higher levels of activity than pups given either 0.01 or 5.0
mg/kg NPA.

Sniffing of 11-day-olds was also unaffected by

EEDQ treatment.

As in Experiment 1, 5.0 mg/kg NPA-treated

pups had higher levels of sniffing than 0.01 mg/kg NPA- or
saline-treated pups.

Seventeen-day-old pups' locomotor activity and sniffing
were affected by EEDQ treatment.

When EEDQ inactivated D1

and D2 receptors in the unprotected/EEDQ condition,
locomotor activity of NPA (0.01 mg/kg) treated pups was
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enhanced on Day 2, as compared with the pups in

protected/EEDQ condition.

Both the unprotected/EEDQ and

protected/EEDQ conditions had lower levels of activity on
Day 4 after 0.01 mg/kg and 5.0 mg/kg NPA than did pups in

the unprotected/vehicle condition.

Sniffing data showed

response patterns similar to Experiment 1, with 5.0 mg/kg

NPA enhancing sniffing behavior significantly more than 0.01

mg/kg NPA.

On Day 1, 5.0 mg/kg NPA produced higher sniffing

counts in the two EEDQ conditions (protected and
unprotected) than in the unprotected/vehicle condition; also
on Day 2, pups given 0.01 mg/kg NPA showed higher sniffing
counts when previously given EEDQ (protected and
unprotected) than if given vehicle.
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Discussion

In the present study, dose-dependent effects of NPA

were established for sniffing and locomotor activity in both
11- and 17-day-old pups.

In Experiment 1, locomotor

activity of 17-day-olds was typically increased by NPA, with
0.01 mg/kg NPA producing the highest levels of activity.
For 11-day-old pups, however, NPA generally decreased
locomotor activity in comparison to saline-treated pups.

Sniffing of 11- and 17-day-olds was enhanced in a dose-

dependent fashion by NPA; 5.0 and 1.0 mg/kg produced higher
counts of sniffing than lower doses of NPA or saline.

In general, results for 17-day-old pups are consistent
with previous research, as NPA and quinpirole have been
shown to increase locomotor activity (McDougall, Crawford, &
Nonneman, 1992; McDougall et al., 1990).

Moody and Spear

(1992) have shown that quinpirole increases forward
locomotor activity in all ages including 10- and 21-day-old

pups; whereas, SKF 38393-indUced increases in locomotor
activity which were most pronounced for 3- and 21-day-old

pups and sniffing was first observed at 10-days-old.

Combinations of quinpirole and SKF 38393 maximally increased
locomotor activity in 10-day-olds.

Researchers have also

shown locomotor activity and sniffing to increase in 11-day
olds in response to quinpirole and the nonselective dopamine
agonist, apomorphine (McDougall et al., 1990; Moody & Spear,
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1992; Shalaby & Spear, 1980).

Importantly, these results

are in contrast with the results of Experiment 1, as NPA was
shown to have no effect on the locomotor activity of 11-day

old pups (See Figure 1).

It is likely that this discrepancy

is due to potency considerations, as NPA is much more potent

than apomorphine or quinpirole.

Thus, it is possible that a

lower dosage is necessary to produce an increase in
locomotor activity in 11-day-old pups.
The present results indicate that lower levels of NPA,
compared to higher levels, increase locomotor activity in
17-day-olds.

In general, previous findings conflict with

this result.

McDougall, Crawford, and Nonneman (1992) found

increased locomotor activity with higher doses of NPA (1.0
compared to 0.1 mg/kg), but locomotor activity was defined
differently in that study and probably more reflects general
stereotyped behavior.

Other studies have also shown that

higher doses of D1 and D2 agonists increase locomotor
activity in younger animals.

For example, larger doses of

SKF-38393 and quinpirole typically increase forward

locomotion for 3-, 10-, and 21-day-old pups (Moody & Spear,
1992), and for 11- and 17-day-olds (McDougall et al., 1990).

Of course, these selective agonists are not as potent as
NPA.

Consistent with the present results, increasing doses

of apomorphine were shown to decrease locomotor movements in

younger animals (Shalaby & Spear, 1980).
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The dose-dependent increase in NPA-induced stereotyped

sniffing reported here is consistent with past research, as

Moody and Spear (1992) found increased sniffing with higher
doses of SKF-38393 in 10-day-olds.

Shalaby and Spear (1980)

also reported increased sniffing for 7- and 14-day-old pups
with increased apomorphine doses.

Sniffing also increases

in ll-day-olds in response to quinpirole (McDougall,

Crawford, & Nonneman, 1992).

Stereotyped sniffing requires

both D1 and D2 receptor activation, suggesting that both D1
and D2 receptors were fully activated for 11- and 17-day-old
pups.

Adult studies have shown that low levels of dopamine

agonists decrease locomotor activity (Arnt, 1987), possibly
due to autoreceptor activation; whereas, activation of

postsynaptic D1 and D2 receptors with higher doses of
dopamine agonists increase locomotor activity and sniffing
in rats (Arnt, 1987; Clark & White, 1987).

It has been

suggested that autoreceptors do not develop in the rat until
after PD 35 (Shalaby & Spear, 1980).

This would indicate

that low doses of dopamine agonists should increase
locomotor activity in younger rats.

The present results are

consistent with the hypothesis that autoreceptors are not

present in 11- or 17-day-old rat pups.

Similar to adults,

both 11- and 17-day-olds showed enhanced sniffing behavior

with higher doses of NPA, indicating that dopamine agonist
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induced stereotyped behaviors are similar for younger rats
as well as adults.

In Experiment 2, EEDQ inactivation of D1 and D2
receptors was behaviorally assessed for II- and 17-day-old
rat pups using NPA.

In general, 11- and 17-day-old pups did

not display aduit typical responses to EEDQ, as NPA-induced
behavior was not inactivated by EEDQ.

McDougall, Crawford,

and Nonneman (1992) found similar results for 17-day-old
pups.

Although 11-day-olds do not show full receptor

recovery after 8 days as do 17-day-olds, no evidence showed
that EEDQ affected behaviors.

Both locomotor activity and

sniffing patterns of the pups were similar in both
Experiments.
EEDQ pretreatment paradoxically enhanced some of the
behaviors of 17-day-old pups.

When D1 and D2 receptors were

inactivated by EEDQ (the unprotected/EEDQ condition)

locomotor activity was enhanced on Day 2 by 0.01 mg/kg NPA,
compared with pups whose D1 and D2 receptors were left
intact (protected/EEDQ).

Sniffing behavior was also

enhanced by both EEDQ conditions (protected and
unprotected), as 5.0 mg/kg NPA produced higher sniffing

counts on Day 1, compared with the unprotected/vehicle
condition; 0.01 mg/kg NPA also produced increased activity
on Day 2 in both EEDQ pretreatment conditions.

A similar

enhancement of locomotor activity after EEDQ induced
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receptor inaetiyation has previously been reported

(McDougall, Crawford, & Nonneman, 1992).

One possible

explariation is that 01 and D2receptGrs rebover faster in

young rats than adults.

This pdssibility appears plausible,

since locomotor activity enhancement did not occur until day

2.

Although the absence of this effect oh 0^

difficult to explain.

is

This possibility also cannot explain

the EEDQ-induced enhancement of sniffing on Day 1.

Another

possibility is that the D1 and D2 receptors still

functioning after EEDOinaetivation are sensitized by EEDQ
and become hyper-responsive to NPA.

Thus, the receptors

remaining may still be able to fully mediate behavior.
Although EEDQ inactivation of dopamine receptors is greater
for adult rats than pups (Crawford et al., 1992; Crawford et

al., 1991), increases in sniffing behavior two days after
EEDQ treatment have been reported in adult rats (Meller et
al., 1989).

Meller et al. suggest that the enhanced

sniffing may be the result of a sufficient number of

dopamine receptors being available for sniffing behavior
without competing behaviors interfering.
A number of adult studies indicate that EEDQ treatment

results in a loss of responses to dopamine D2 agonists (Arnt
& Hyttel, 1989; Arnt et al., 1988; Hamblin & Creese, 1983;
Meller et al., 1989).

The D2 agonist, quinpirole had no

effect on stereotyped behaviors after EEDQ treatment,
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indicating a sufficient depletion of D2 receptors in the
adults (Arnt et al., 1988).

McDougall, Crawford, and

Nonneman (1992) also found EEDQ treatment to inhibit NPA-

induced increases in locomotor activity and decreases in
grooming behavior for at least two days in 90-day-old rats.
A number of possibilities exist for the age-dependent

behavioral differences in response to EEDQ treatment.

One

possibility is that dopamine receptors may be unaffected by
EEDQ in the young rat.

However, Crawford et al. (1992)

found binding sites for 17-day-old-rats to be approximately
69% when compared with adult rats with an 86% depletion
rate.

This amount of inactivation should be sufficient to

disrupt behavior in the younger animals (McDougall,
Crawford, & Nonneman, 1992).

Similar depletion rates are

found for 11-day-old pups in comparison to 17-day-olds, and
in contrast full recovery did not occur for the 11-day-olds

even after eight days (Crawford et al., 1991).

Even after

24 hours, receptor inactivation is still apparent in the
younger rats, although they do show faster recovery rates
than older rats (Crawford et al., 1992; Crawford et al.,
1991; Leff et al., 1984).

Another possibility is that the young rat may have a
receptor reserve sufficiently large enough to compensate for
the loss of D1 and D2 receptors.

Arnt et al. (1988)

suggests that a receptor reserve may exist for D1 mediated
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behaviors, thus explaining the lack of effect of EEDQ

treatment on those behaviors.

However, it is unlikely that

11- and 17-day-old pups have an overabundance of D1 and D2

receptors, since these receptors are still below adult
levels (Murrin & Zeng, 1986; Rao et al., 1991; Rowlett et
al., 1989; Zeng et al., 1988).

A receptor reserve

hypothesis also does not account for the 0.01 mg/kg NPA-

induced increases in locomotor (in the unprotected/EEDQ
condition) and sniffing (in both EEDQ conditions) in 17-day

olds on Day 2; or the 5.0 mg/kg NPA-induced increase in
sniffing on Day 1 for the protected and unprotected/EEDQ
conditions, since these findings were not seen across all
days.

A last possibility is that dopamine receptors in the
young rat may be sensitized by EEDQ treatment, thus
compensating for those destroyed.

Some results from

Experiment 2 can best be explained by this possibility,
since EEDQ produced higher activity levels when D1 and D2
receptors were inactivated on Day 2 for 17-day-old pups.
However, the general inability of EEDQ to inhibit NPA-

induced behaviors is still unexplained.

It may be that

postsynaptic mechanisms are insufficient for explaining this
phenomenon, and EEDQ is acting at presynaptic sites to
produce these behaviors.

Although it is known that DOPAC

levels are elevated in adult rats, but not rat pups, treated
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with EEDQ, few studies have assessed the possibility that

presynaptic sites may be responsible for the ontogenetic
differences in EEDQ-induced responses.

For both Experiments 1 and 2, day-dependent increases
in locomotor activity were generally observed for 17-day-old

pups treated with NPA.

Only for the unprotected/EEDQ

condition did activity significantly decrease with 0.01
mg/kg NPA from Day 2 to Day 4.

Interestingly, 11-day-olds

in Experiment 1 showed no increase in activity over days
with NPA treatment, although in Experiment 2 a significant
increase in activity from Day 1 to Day 2 was noted for 0.01
mg/kg NPA.

Sniffing behavior showed day-dependent

increases, as 11- and 17-day-olds in Experiment 1 exhibited

general increases in sniffing over testing days with all
doses of NPA.

In Experiment 2, 11-day-olds in the 5.0 mg/kg

NPA group showed day-dependent increases in sniffing;

whereas, 17-day-olds showed this increase in the

unprotected/vehicle condition only.

As with locomotor

activity, the unprotected/vehicle pups had increased levels
of sniffing from Day 1 to Day 2 with 0.01 mg/kg NPA, which
then decreased on Day 4; this was also seen in the
protected/EEDQ condition.

In Experiment 1, a drug-sensitization effect appears to
be occurring for the 17-day-old pups in both locomotor

activity and sniffing, and for ll-day-old sniffing
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responses.

Although some researchers have argued that

sensitization does riot occur in rats under PD 21 to

amphetamine (Kolta et al., 1990), others have observed
sensitization-like effects with NPA treatment in preweanling
rat pups (McDougall, Crawford, & Nonneman, 1992).

Performance of the 17^day-olds in Experiment 2 is also
consistent with drug-sensitization.

The decrease in

locomotor activity and sniffing on Day 4 for NPA (0.01
mg/kg) treated pups in the unprotected/vehicle condition,
may suggest D1 and D2 receptors have been sensitized by

EEDQ, making it impossible for NPA to induce its normal
sensitizing effects.

EEDQ has been shown to inactivate receptor types other

than dopamine D1 and D2, including: alpha-adrenergic,

serotonin and GABA receptors (Meller, Bohmaker, Goldstein, &
Friedhoff, 1985; Miller, Lumpkin, Galpern, Greenblatt, &
Shader, 1991).

By selectively protecting dopamine receptor

subtypes with D1 and d2 antagonists, behavioral effects due
to nondopaminergic receptors are assumed to be equal between
protected and,unprotected conditions (Hamblin & Creese,
1983; Henry et al., 1987; Leff et al., 1984; Meller et al.,

1989).

Dopamine receptor subtypes D1 and D2 were

selectively protected by using sulpiride and SCH 23390 in
the current study, thus allowing dopaminergic and

nondopaminergic effects to be separated.
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As seen on Day 2,

17-day-old pups were significantly less active in the
protected/EEDQ condition after 0.01 jng/kg NPA treatment, as

compared with the unprotected conditions, suggesting
nondopaminergic processes affected locomotor activity in the
older pups.

In summary, low doses of NPA increased locomotor
activity in 17-day-old pups; however, ll-day-old pups
displayed lower activity levels with NPA.

It is possible

that 11-day-olds require a lower dose of NPA than those

tested here to display increases in locombtor activity.
Sniffing behavior was enhanced for both 11- and 17-day-olds,
with 5.0 mg/kg producing the most pronounced effect.

EEDQ pretreatment did not produce an adult-typical response
in either 11- or 17-day-old pups; and in some cases produced

an enhanced effect in 17-day-olds.

These results suggest

that either dopamine receptors recover faster in yodng
animals or that a sufficient numbers of dppamine receptors
were left intact after EEDQ treatment to mediate these
behaviors.
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